INTRODUCTION
The adipocyte uses well regulated transcriptional programs to adapt to environmental inputs through storage of calories as triglycerides and secretion of adipokines and other factors (Rosen and Spiegelman, 2006) . PPARg is a key factor controlling the importance of adipose tissue in whole-body glucose metabolism (Evans et al., 2004; Lehrke and Lazar, 2005; Saltiel and Olefsky, 1996; Sugii et al., 2009; Tontonoz and Spiegelman, 2008) . PPARg is a member of the nuclear hormone receptor (NR) family and is highly enriched in adipose tissue, where it plays a critical role in adipocyte differentiation, insulin sensitivity, and adipokine/cytokine secretion (Evans et al., 2004; Imai et al., 2004; Rangwala and Lazar, 2004; Tontonoz and Spiegelman, 2008) . Although its endogenous ligand is poorly understood, PPARg is the molecular target for the thiazolidinedione (TZD) class of insulin-sensitizing drugs used to treat type 2 diabetes.
Transcriptional control by NRs, including PPARg and others, depends on multiprotein coregulatory complexes (Feige and Auwerx, 2007; Fowler and Alarid, 2004; Hermanson et al., 2002) . In general, corepressor complexes are recruited to NRs in the absence of ligand, whereas coactivator complexes are recruited to NRs in the presence of agonists (Lonard and O'Malley, 2005) . Coactivators and corepressors modulate gene transcription by a variety of mechanisms including histone acetylation, chromatin remodeling, and direct interactions with basal transcription complexes (Collingwood et al., 1999) . There are several coactivators, such as CBP, PGC1a, and CRTC2, that are known to play important roles in metabolic control (Handschin and Spiegelman, 2008; Revilla and Granja, 2009; Wang et al., 2010) . However, the role and underlying mechanisms of corepressor function in metabolic tissues remains unclear. Two major NR corepressors are the silencing mediator of retinoid and thyroid hormone receptors (SMRT) and the nuclear receptor corepressor (NCoR) (Chen and Evans, 1995; Horlein et al., 1995) . It has been shown that downregulation of SMRT and NCoR expression in 3T3-L1 cells leads to enhanced adipocyte differentiation, in part through increased PPARg transcriptional activity (Yu et al., 2005) . However, their role in adipogenesis, adipocyte function, and glucose metabolism in vivo remains uncertain. Since whole body NCoR deletion is embronically lethal (Jepsen et al., 2000) , we generated adipocytespecific NCoR knockout (AKO) mice to assess the role of this corepressor in glucose metabolism, insulin sensitivity, and adipogenesis. We show that AKO mice develop increased adiposity on HFD relative to WT controls. Despite this increase in obesity, the AKO animals exhibit enhanced systemic insulin sensitivity, improved glucose tolerance, and decreased adipose tissue inflammation. Taken together, these features phenocopy the effects of systemic TZD treatment.
RESULTS

NCoR Deletion in Adipocytes
To investigate the specific role of adipocyte NCoR on adipogenesis and on the development of insulin resistance in response to HFD feeding, we generated adipocyte-specific knockout mice (AKO) using the Cre-lox system (NCoRfl/fl; aP2-Cre +/-) (Figures 1A and 1B). As controls, floxed NCoR mice that do not express Cre recombinase (Cre) were used (NCoRfl/fl; ap2-Cre À/À ), referred to, hereafter, as WT. As expected, NCoR expression was greatly diminished in the epididymal adipose tissue of AKO mice ( Figure 1C ). However, since aP2/Fabp4 can also be expressed in macrophages, we determined whether aP2 Cre-mediated deletion of NCoR could be detected in this cell type. There was no decrease in NCoR expression in intraperitoneal (IP)-macrophages from the AKO mice ( Figure 1C) , consistent with previous studies using this ap2-cre mouse line, showing adipocyte restricted expression (He et al., 2003; Qi et al., 2009; Sabio et al., 2008; Sugii et al., 2009 ). This explains the $70% decrease in NCoR expression in whole epididymal adipose tissue, since NCoR is not deleted in macrophages or other nonadipocyte cell types present in this tissue. Interestingly, the magnitude of NCoR depletion in subcutaneous WAT and BAT was closer to 90%, most likely reflecting a lower amount of nonadipocytic cells, such as immune cells, in these depots. As also shown in Figure 1D , there was no NCoR deletion in any other tissue examined. SMRT is another corepressor, which in some contexts can function similarly to NCoR, but there were no changes in SMRT expression in the AKO mice in any tissues ( Figure 1E ).
AKO Mice Are More Obese Than WT after HFD Feeding
To investigate the functional significance of adipocyte-specific NCoR deletion, both WT and AKO mice were fed a 60% high- Values are fold induction of gene expression normalized to the housekeeping gene Gapdh and expressed as mean ± SEM, n = 8-10 in (C)-(E), *p < 0.05, **p < 0.01 for AKO versus WT. See also Table S1. fat diet (HFD) for up to 17 weeks, starting at 8 weeks of age. As expected, WT mice became obese, but the AKO mice were even more obese as shown in Figure 2A . Thus, the body weight of the AKO mice was $15% greater than WT (Figure 2B) and this was accompanied by a 10% increase in food intake ( Figure 2C ). To further assess body composition changes accompanying this increase in obesity, MRI analyses were performed. As shown in Figures 2D-2F , the AKO mice exhibited an increased volume of both subcutaneous and visceral fat. Accordingly, epididymal fat mass doubled in AKO mice compared to WT ( Figure 2G ), while there was no difference in lean body mass (data not shown). Given that PPARg plays a central role in the promotion of adipogenesis, these results suggest constitutive activation of adipose tissue PPARg. Consistent with this interpretation, Figure 2H shows increased expression of the adipogenic PPARg response genes FAS, ACC, SREBP1c, SCD1, and SCD2 in AKO adipose tissue (Djaouti et al., 2010; Lessard et al., 2007; Paton and Ntambi, 2009; Sugii et al., 2009 ).
Deletion of NCoR in Adipose Tissue Protects against HFD-Induced Systemic Insulin Resistance
Obesity leads to glucose intolerance as well as insulin-resistance in adipose tissue, liver, and muscle. Therefore, we assessed glucose homeostasis and insulin sensitivity in lean chow-fed and HFD-fed WT and AKO mice. No changes in glucose or insulin tolerance, BW, fat-pad weight, or fasting insulin level, were noted in the lean chow-fed mice between genotypes (Figure S1 available online). In contrast, in the context of HFD/ obesity, marked phenotypic changes in glucose and insulin homeostasis emerged in the AKO mice. Basal insulin level was reduced ( Figures 3A and 3B) , and upon glucose and insulin tolerance test, the AKO mice showed an enhanced hypoglycemic response to the injected insulin ( Figure 3C ), as well as improved glucose tolerance compared to controls ( Figure 3D ). In aggregate, these results argue strongly for improved systemic insulin sensitivity as a result of adipocyte NCoR deletion.
To more accurately quantify in vivo insulin action and to assess tissue-specific sites of insulin sensitivity, hyperinsulinemic/ euglycemic clamp studies were performed. The amount of exogenous glucose required to maintain euglycemia (GIR) and the glucose disposal rate (GDR) during the clamp studies was substantially higher in the AKO mice compared to WT ( Figures  3E and 3F ). The insulin-stimulated glucose disposal rate (IS-GDR), which primarily reflects skeletal muscle insulin sensitivity and insulin's ability to suppress hepatic glucose production (HGP), which reflects hepatic insulin sensitivity, was also improved in the AKO group ( Figures 3G-3I) . Finally, the ability of insulin to suppress plasma FFA levels provides an indication of adipose tissue insulin sensitivity, and FFA suppression was nearly twice as great in the AKO mice compared to WT (Figure 3J) . We also harvested fat, liver, and muscle tissue for ex vivo measurements of insulin action. As seen in Figures 3K-3M , insulin-stimulated Akt phosphorylation was augmented in all three tissues in the AKO mice compared to WT. Livers of the obese AKO mice were markedly less steatotic compared to WT by HE staining, with reduced expression of the lipogenic genes, SREBP1c, FAS, and ACC ( Figure S2 ). Similarly, in muscle, we found a marked decrease in TAGs, DAGs, and ceramides in the AKO group ( Figure S2 ). Taken together, these data demonstrate that deletion of NCoR from adipocytes leads to a marked improvement in systemic insulin sensitivity, and these effects were expressed in all three major insulin target tissues, muscle, liver, and adipose tissue.
Adipocyte Function in WT and AKO Mice
Obesity represents an enlargement of adipose tissue to store excess energy, and this is mostly accomplished by hypertrophy of fat cells, with hyperplasia generally assuming a smaller role. In chow-fed animals, the average epididymal adipocyte diameter was 60 mm, and in age-matched HFD/obese mice, fat-cell diam- Table S1 and Figure S1 .
eter increased dramatically to 219 mm in WT mice. Interestingly, in the AKO group, the increase in adipocyte size was less on HFD (169 mM) ( Figure 4A Figure 4B ) were increased in the HFD AKO mice, providing an additional potential mechanism for enhanced PPARg signaling. In the lean chow-fed mice, no changes in PPARg gene expression were noted in any of the adipose tissue depots examined ( Figure S3 ). We measured tissue cathepsin D activity, perilipin content, and tunnel staining and found that levels of cathepsin D and perilipin were lower in the AKO mice, as was tunnel staining, indicative of lower rates of apoptosis/ necrosis ( Figures 4C-4E ). Brown adipose tissue (BAT) mass and BAT-related gene expression were unchanged in the AKO mice ( Figure S4 ).
Besides storing lipids, adipose tissue functions as an endocrine organ, secreting a large number of polypeptide hormones, termed adipokines, which can modify systemic glucose homeostasis and insulin sensitivity. We measured adipokine levels in the AKO mice and found lower levels of leptin, resistin, PAI-1, but higher levels of HMW-adiponectin ( Figure 4F ), indicating that deletion of NCoR in adipocytes led to an adipokine profile favoring insulin sensitivity.
In adipose tissue, insulin promotes the uptake and storage of fatty acids in the form of triglycerides and inhibits lipolysis of stored triglycerides. Circulating levels of free fatty acids (FFA) were lower in the AKO mice ( Figure 4G ), suggesting lower rates of lipolysis in the adipose tissue. We also measured insulin-stimulated glucose uptake in primary adipocytes and as seen in Figure 4H , the ability of insulin to enhance glucose transport was 30% higher in AKO versus WT adipocytes. This directly demonstrates cell autonomous insulin sensitivity in AKO cells, consistent with the insulin signaling data provided in Figure 3M . Conditioned media (CM) harvested from LPS treated RAW264.7 macrophages contains high levels of secreted cytokines which can inhibit insulin-stimulated glucose transport. Interestingly, when adipocytes were treated with RAW 264.7 cell CM, the expected inhibition of glucose transport was observed in WT adipocytes, but this effect of CM was attenuated in the AKO cells ( Figure S3 ).
Macrophage Infiltration and Inflammation in Adipose Tissue
Large numbers of adipose tissue macrophages (ATMs) accumulate in obesity and substantial evidence exists pointing to an etiologic role for these cells in the development of chronic tissue inflammation and insulin resistance/diabetes Lumeng et al., 2007; Nguyen et al., 2007; Weisberg et al., 2003; Xu et al., 2003) . Thus, SVCs of epi-WAT depots from the two groups were isolated and stained with F4/80 and CD11b antibodies. This immunohistochemical analyses showed a large increase in F4/80 and CD11b double-positive macrophages in the WT mice after 17 weeks of HFD while ATM accumulation was much less in the AKO group ( Figure 5A ). Consistent with this, adipose tissue F4/80 mRNA expression was lower in the AKO mice ( Figure 5B ). ATMs often surround dead adipocytes to form crown-like structures (CLS) and there were fewer CLS in the AKO mice compared to WT mice ( Figure 5C ). These findings demonstrate that ATM content is diminished in the AKO animals, despite the fact that they are more obese.
ATMs are heterogeneous, and there are at least two subpopulations of F4/80
+ ATMs-one of which is positive and the other negative for CD11c. The CD11c+ (triply positive, (Hevener et al., 2007; Li et al., 2010; Lumeng et al., 2007; Nguyen et al., 2007) . As shown in Figures 5D and 5E, there was a marked decrease in CD11c + ATMs in the AKO mice compared to WT. Most proinflammatory genes, including TNFa, IFNg, iNOS, IL12p40, COX2 , and MCP-1, were reduced in the AKO mice ( Figure 5F ), while expression of the noninflammatory M2 marker genes, arginase and Mgl2, was increased. To expand this analysis, we measured these mRNAs in adipocytes compared to SVCs ( Figure S5 ). These results were quite consistent with the whole adipose tissue data in that proinflammatory gene expression was generally decreased in both the SVCs and adipocytes from AKO mice.
To assess the mechanisms underlying the decreased ATM content in AKO mice, we measured the effects of CM from WT and AKO primary adipocytes to induced macrophage chemotaxis. AKO CM-mediated in vitro chemotaxis was markedly decreased compared to WT CM ( Figure 5G ), fully consistent with the reduced ATM content in AKO adipose tissue. We studied this concept further by directly measuring macrophage migration into adipose tissue using an in vivo macrophage tracking technique. With this approach, circulating monocytes were obtained from a WT donor mouse and labeled with fluorescent PKH26 dye ex vivo. The labeled monocytes were then injected into recipient HFD WT or HFD AKO mice. As seen in Figure 5H , there was a substantial decrease in labeled macrophage appearance in adipose tissue in the AKO mice. These data were even more revealing when we examined the subpopulations of labeled macrophages between the genotypes. With this analysis, ( Figure 5I ) there is an even greater decrease in the number of recruited macrophages which express CD11c, while at the same time there is an increase in the CD11c À macrophage population in the AKO mice.
AKO Mice Are Relatively Refractory to PPARg Stimulation TZD treatment leads to increased insulin sensitivity, and we assessed this by treating HFD WT and HFD AKO mice with the PPARg agonist Rosiglitazone for 3 weeks, followed by hyperinsulinemic-euglycemic clamp studies. The data in Figure 6 demonstrate that the WT mice displayed increased muscle ( Figure 6A ), liver ( Figure 6B ) and adipose tissue ( Figure 6C ) insulin sensitivity after Rosiglitazone treatment. The AKO mice were already insulin sensitive prior to drug treatment ( Figure 3 ) and Rosiglitazone had no further effects in muscle and fat, but did induce even greater insulin sensitivity in liver ( Figure 6 ). This suggests that the AKO mice are relatively resistant to exogenous PPARg stimulation, most likely because adipocyte PPARg target genes are already derepressed by the NCoR deletion. Unwanted side effects of TZD treatment include hemodilution and increased heart weight. Interestingly, neither were observed in the AKO mice, while, as expected, the effects of Rosiglitazone treatment to cause hemodilution were the same in both genotypes ( Figure S4 ). To further explore the mechanisms of this relative refractoriness to TZD treatment, we examined PPARg expression and its phosphorylation state in adipose tissue. Choi et al. have recently shown that CDK5-mediated phosphorylation of PPARg at serine 273 is an important regulatory event (Choi et al., 2010) . In turn, PPARg agonist treatment leads to dephosphorylation of PPARg serine 273 and dephosphorylation at this site confers an active transcriptional program, consistent with an insulin sensitive state. In our current studies, we found that PPARg mRNA ( Figure 4B ) and protein expression were increased in the AKO mice in adipose tissue extracts ( Figure 6D ) or in primary adipocytes ( Figure 6E ). Importantly, a substantial decrease in serine 273 phosphoPPARg was also observed in both adipose tissue and primary adipocytes, and the ratio of phospho-PPARg to total PPARg protein was markedly reduced in the HFD-fed AKO mice compared to WT. It is unlikely that this decreased PPARg phosphorylation was due to decreased CDK5 activity, since CDK5 protein levels and, more importantly, phospho-CDK5 levels, were comparable between WT and AKO mice ( Figures  6D and 6F) . Furthermore, phosphorylation of Rb, another cellular substrate of CDK5, was intact in the AKO cells ( Figure 6G ). Rosiglitazone treatment ( Figure 6F ) led to decreased PPARg serine 273 phosphorylation in WT animals, as previously reported by Choi et al. (Choi et al., 2010) . Since nonphosphorylated PPARg has insulin sensitizing actions, the finding that NCoR depletion inhibits this phosphorylation event is important and could contribute to the AKO phenotype. To further explore the mechanisms for this effect, we treated WT and AKO primary adipocytes with TNFa. TNFa is known to activate CDK5, and Figure 6H shows that TNFa treatment led to an increase in serine 273 PPARg phosphorylation in WT adipocytes. Importantly, TNFa did not increase serine 273 PPARg phosphorylation in AKO cells, demonstrating a cell autonomous effect of NCoR to facilitate CDK5-mediated PPARg phosphorylation.
The molecular events underlying PPARg phosphorylation were assessed with a series of coimmunoprecipitation and mammlian two-hybrid assays. In these studies, we used a luciferase reporter assay driven by Gal4-PPARg coupled with VP16-NCoR constructs, encompassing NCoR residues 1-740 (NCoR-N), 742-1798 (NCoR-M), and 1803-2439 (NCoR-C). The data clearly show a direct interaction between PPARg and NCoR, and the NCoR interaction site is located in the RID-containing C terminus. Rosiglitazone treatment strongly inhibits this interaction almost to base line values ( Figure 6I ). We also performed coimmunoprecipitation experiments and confirmed earlier reports (Yu et al., 2005) , that PPARg coprecipitates with NCoR in WT cells (data not shown). More importantly, we also found that PPARg readily precipitates with CDK5 in WT cells with $55% less PPARg coprecipitated in the AKO cells (Figure 6J) . Rosiglitazone causes dissociation of the PPARg,NCoR complex ( Figure 6I ) and this leads to decreased CDK5/PPARg coprecipitation in WT cells ( Figure 6J ). Transient transfection assays showed that full-length NCoR and the NCoR C terminus enhance TNFa-stimulated CDK5 phosphorylation of PPARg serine 273 in HEK293T cells ( Figure 6K ). In the two-hybrid system ( Figure 6L ) we used Gal4-CDK5 and VP16-PPARg to show direct association between PPARg and CDK5. Expression of NCoR increases this interaction, while Rosiglitazone treatment (which causes NCoR dismissal) decreases this interaction ( Figure 6M ). In the two-hybrid system, we also found no evidence for a direct interaction between NCoR and CDK5 (data not shown). Taken together, these results indicate that NCoR directly interacts with PPARg and, through an allosteric effect, enhances the ability of PPARg to associate with CDK5. When CDK5 activity is stimulated, as with TNFa treatment in vitro or obesity-induced 
Studies of Gene Expression
Since NCoR can interact with other transcription factors, in addition to PPARg, we compared gene expression profiles in epi-WAT from HFD-fed WT and HFDfed AKO mice. Fold change was calculated against the transcript levels of the WT group. The results revealed that 163 genes were upregulated and 107 genes were downregulated in the AKO group compared to WT. The most significantly enhanced pathway in the upregulated group was the annotated PPARg signaling pathway. qPCR was used to better quantitate a group of PPARg response genes ( Figures 7A and 7B ) in addition to those already shown in Figure 2H . These results demonstrate that these genes were uniformly upregulated in the AKO mice compared to WT, and that Rosiglitazone treatment led to increased expression of these genes in WT animals but had no effect to further enhance expression in the AKO mice. These results fortify the conclusion that adipocyte NCoR deletion leads to an activated PPARg transcriptional state which is not further enhanced by PPARg ligand (TZD) treatment. Consistent with this, RGS2 is a gene known to be downregulated by PPARg activation and Figure 7B shows that RGS2 expression is decreased in the AKO mice and that Rosiglitazone treatment decreases RGS2 expression in WT but not AKO animals. Additional KEGG analysis revealed that upregulated genes were also significantly enriched in functionally annotated pathways including: fatty-acid metabolism, insulin signaling pathway, and mitochondria and lipid metabolic process. Downregulated genes were significantly enriched for functional annotations such as natural killer cell-mediated toxicity and immune system process. The genes associated with the enriched functional pathways mentioned above are shown in Table S2 .
To probe the mechanisms of ligand-independent gene upregulation in AKO cells, we conducted ChIP assays for the PEPCK promoter. As seen in Figure 7C , Rosiglitazone treatment led to the expected increase in coactivator (SRC3) recruitment to the promoter in WT cells, whereas in AKO cells, SRC3 occupancy was already high in the absence of ligand, with no further increase due to Rosiglitazone. This pattern corresponds quite closely to the gene expression results shown in Figure 7A (first box). In contrast, Gpd1 is a PPARg-induced gene that was not constitutively upregulated in the AKO cells and ChIP assays showed the classical pattern of Rosiglitazone-mediated SRC3 recruitment in both WT and AKO cells.
DISCUSSION
Adipose tissue serves as an integrator of various physiological pathways and is at the key cross roads for regulation of energy balance and glucose homeostasis (Cusi, 2010; Goossens, 2008; Halberg et al., 2008; Kahn and Flier, 2000; Qatanani and Lazar, 2007) . Nuclear receptors are a family of transcription factors which modulate many aspects of biologic function, including glucose and energy homeostasis (Evans et al., 2004; Francis et al., 2003; Tontonoz and Spiegelman, 2008) . NCoR is a major corepressor of nuclear receptor function (Glass and Rosenfeld, 2000) and, therefore, should be a regulator of energy and glucose balance. In the current studies, we have generated adipocyte-specific NCoR knockout mice and have conducted detailed in vivo and in vitro studies of adipocyte biology, obesity, inflammation, and insulin resistance. We find that deletion of NCoR from adipocytes leads to a phenotype which phenocopies constitutive PPARg activation. The AKO animals become more obese on HFD than WT mice, due to increased adipocyte hyperplasia. Despite the increased adiposity, the AKO mice demonstrate decreased ATM content, reduced tissue inflammation, cell autonomous adipocyte insulin sensitivity and enhanced systemic insulin sensitivity. Interestingly, they are also relatively refractory to Rosiglitazone treatment. Although NCoR can serve as a corepressor for multiple nuclear receptors, it is quite striking that the major phenotype in AKO mice can be traced to unrestrained PPARg activity. This allows us to infer that in adipocytes, the dominant function of NCoR is to repress PPARg. Furthermore, since genetic deletion of NCoR in adipocytes is the initiating event in our model, these studies demonstrate that unleashing PPARg only in adipose tissue is sufficient to produce the systemic effects seen with in vivo TZD treatment, indicating the importance of adipose tissue for the metabolic effects of these drugs. Table S1 and Table S2 .
The AKO mice exhibited enhanced systemic insulin sensitivity as demonstrated by improved oral glucose tolerance with a reduction in hyperinsulinemia, and a greater hypoglycemic response to insulin during the insulin tolerance test. This increased insulin sensitivity was quantitated using the hyperinsulinemic/euglycemic clamp, as well as ex vivo tissue analyses. Importantly, the improved insulin sensitivity was not simply confined to adipose tissue, since increased hepatic and skeletal muscle insulin sensitivity was clearly demonstrated in the glucose clamp studies, with a 95% increase in IS-GDR (skeletal muscle insulin sensitivity) and 136% increase in hepatic insulin sensitivity (HGP suppression). These in vivo findings were strongly supported by the tissue measures of insulin signaling which showed improved insulin-stimulated Akt phosphorylation in all three insulin target tissues in the AKO animals.
Our studies also explored the physiologic mechanisms underlying the amelioration of insulin resistance due to adipocyte NCoR deletion. For example, it is well known that adipocytes secrete adipokines which can have systemic endocrine effects to modulate the tone of insulin action. We found that circulating levels of HMW adiponectin were increased, whereas, resistin levels were decreased in the AKO mice, and this combination could certainly improve insulin resistance. The AKO adipocytes also displayed increased insulin-stimulated glucose transport compared to WT primary adipocytes. Furthermore, the effect of macrophage CM to cause insulin resistance in adipocytes was partially abrogated in the AKO cells similar to a TZD-treated state. This demonstrates increased cell autonomous adipocyte insulin sensitivity, providing an additional mechanism for improved in vivo insulin resistance.
It has been widely reported that chronic tissue inflammation can be a major cause of insulin resistance and that macrophage-mediated proinflammatory effects are an underlying mechanism (Donath and Shoelson, 2011; Hotamisligil and Erbay, 2008; Olefsky and Glass, 2010) . Here we show that in HFD/obese mice, ATM accumulation was reduced in the AKO group and this was accompanied by decreased expression of proinflammatory genes in the adipose tissue. Interestingly, one of the important chemokines released by adipocytes is MCP-1, and PPARg activation is known to inhibit adipocyte MCP-1 expression and secretion. We found decreased levels of MCP-1 in adipose tissue from the AKO mice, consistent with the activated PPARg phenotype and this could provide an explanation for the decreased ATM numbers and reduced levels of inflammation. Indeed, we provide direct evidence consistent with this idea by showing that CM harvested from AKO compared to WT primary adipocytes has a much lower capacity to stimulate macrophage chemotaxis. In vivo macrophage tracking studies were also consistent with this concept. Here we found that when fluorescently labeled monocytes were injected into recipient HFD WT or AKO mice, a substantial decrease in macrophage appearance in adipose tissue was observed in the AKO animals. Taken together, these data suggest the overall idea that adipocyte NCoR deletion leads to decreased chemokine secretion from adipocytes, causing reduced ATM content and decreased inflammation, contributing to the enhanced state of insulin sensitivity.
It is of interest that the ultimate phenotype of the recruited ATMs is substantially different in the WT versus AKO mice. In WT mice, > 90% of the fluorescently labeled recruited ATMs assume the M1-like, CD11c+ proinflammatory phenotype, whereas, only $50% of the recruited ATMs in the AKO mice become CD11c+. This means that in the AKO mice there is a 6-fold increase in the proportion of these recruited ATMs which become M2-like, CD11c-ATMs. Thus, not only are the chemotactic signals reduced in AKO adipose tissue causing decreased total ATM migration, but differences in tissue cues also promote a higher degree of polarization to the M2-like ATM phenotype.
We were also able to study the WT and AKO mice after Rosiglitazone treatment and found that the predicted effects of this drug to improve insulin sensitivity were readily demonstrated in the HFD/obese WT mice. On the other hand, the HFD AKO mice were refractory to the effects of TZD treatment in adipose tissue and muscle. This is consistent with the PCR and gene array results which showed that the PPARg transcriptional program is fully activated in the AKO adipose tissue and that Rosiglitazone treatment has very little additional effect. On the other hand, a clear improvement in hepatic insulin action was observed in the Rosiglitazone-treated AKO mice. Since the transcriptional effects of Rosiglitazone action involve dismissal of NCoR from PPARg target genes, this mechanism cannot be operative in adipocytes from the AKO mice. However, since NCoR expression was not altered in liver, the Rosiglitazonemediated improvement in hepatic insulin sensitivity could still occur. With this in mind, it is interesting to note that, while Rosiglitazone treatment led to enhanced hepatic insulin action in the AKO mice, pretreatment hepatic insulin sensitivity was already greater in the AKO animals compared to WT. This indicates that in vivo TZD-induced hepatic insulin sensitization includes both direct drug effects in the liver and indirect effects, most likely originating in adipose tissue.
TZD treatment causes fluid retention as manifested by hemodilution, edema, and often times increased heart weight. As measured by hematocrit and heart weight, the AKO mice do not show signs of hemodilution ( Figures S4C and S4D ), demonstrating that the site of action of TZDs to cause edema is outside of the adipocyte, most likely in the kidney, where NCoR and the PPARg system are fully preserved in our mice. Rosiglitazone causes the expected effect on hemodilution in both genotypes ( Figure S4C ), also consistent with a site of action outside of the adipose tissue. These results suggest that adipocyte-specific stimulation of the PPARg program could be an effective means to avoid some of the unwanted side effects associated with classical TZD treatment.
An important finding in these studies involves the status of PPARg phosphorylation at serine 273. Choi et al. have demonstrated that CDK5 can phosphorylate PPARg at position 273 (Choi et al., 2010) , whereas, PPARg agonists lead to decreased phosphorylation at this site. They have also shown that the dephosphorylated form of PPARg is transcriptionally active, inducing a gene signature profile conducive to insulin sensitization. This finding prompted us to examine the status of PPARg serine 273 phosphorylation in our studies. We found that serine 273 phosphorylation was decreased in whole adipose tissue and in isolated adipocytes from the AKO mice compared to WT. This difference was not due to reduced CDK5 activity, since the amount of phospho-CDK5 in adipose tissue and the phosphorylation state of another CDK5 substrate, Rb, was comparable between the two groups. From these findings, we infer that NCoR is necessary for CDK5-mediated PPARg serine 273 phosphorylation. This may also help explain why PPARg agonists cause decreased PPARg serine 273 phosphorylation, since PPARg agonists dismiss NCoR from the PPARg transcriptional complex. This decrease in PPARg serine 273 phosphorylation is likely an important factor in the insulin sensitive phenotype in these mice.
Given the potential importance of this finding to decreased insulin resistance, we conducted experiments to elucidate the mechanisms for the reduced PPARg phosphorylation in the absence of NCoR. TNFa is an activator of CDK5, and Choi et al. have demonstrated that TNFa treatment of adipocytes increases serine 273 PPARg phosphorylation. In the current studies, we found that TNFa treatment of WT primary adipocytes led to increased serine 273 PPARg phosphorylation, whereas, TNFa had no such effect in AKO cells. This demonstrates that the ability of adipocyte NCoR deletion to decrease serine 273 PPARg phosphorylation is a cell autonomous effect. Furthermore, we show that PPARg coprecipitates with CDK5, demonstrating the presence of these two proteins in a molecular complex. Importantly, coprecipitation of PPARg with CDK5 was markedly decreased in the AKO cells. Both two-hybrid and Co-IP studies show a direct interaction between NCoR and PPARg, and this interaction is inhibited by Rosiglitazone treatment. We also show that NCoR enhances TNFa-stimulated CDK5-mediated PPARg serine 273 phosphorylation, while Rosiglitazone treatment, which dissociates NCoR from the complex, inhibits this phosphorylation event. In the two-hybrid system, the data show a direct interaction between PPARg and CDK5, and NCoR has a substantial effect to enhance this association while Rosiglitazone treatment attenuates it. In contrast to the strong inteactions between PPARg and NCoR, and PPARg and CDK5, we found only a negligible direct interaction between NCoR and CDK5. We also observed that TNFa treatment does not increase CDK5/PPARg association, consistent with the view that the TNFa effect is conferred by augmenting the enzymatic activity of CDK5, rather than its association with its PPARg target protein. In sum, when NCoR is decreased by genetic deletion or Rosiglitazone treatment, the CDK5/PPARg interaction is attenuated and subsequent phosphorylation of PPARg serine 273 is reduced. When NCoR expression is enhanced, the interaction between CDK5 and PPARg is augmented, as is PPARg serine 273 phosphorylation. All of these results are consistent with the concept that the NCoR interaction with PPARg produces an allosteric effect to enhance the ability of PPARg to associate with CDK5.
With respect to the constitutively upregulated genes, a transcriptional mechanism would predict low basal coactivator occupancy of the promoter in WT cells with an increase upon Rosiglitazone treatment. Due to NCoR deletion in AKO cells, coactivator occupancy should be high in the absence of ligand with no further increase due to Rosiglitazone. This is precisely the pattern observed in our ChIP studies for SRC3 on the PEPCK promoter ( Figure 7C ). In contrast, Gpd1 is a PPARg gene which was not upregulated in the AKO cells and ChIP assays showed the classical pattern of Rosiglitazone-induced coactivator recruitment in both WT and AKO cells. The degree of insulin sensitivity in adipose tissue and muscle was the same in untreated AKO mice as in Rosiglitazone treated WT animals, and, therefore, it seems logical to suggest that the set of constitutively upregulated genes in the AKO mice, contains the key genes essential for TZD-mediated improvement of insulin sensitivity.
In these studies, we have shown that adipocyte-specific deletion of the corepressor NCoR, specifically activates the PPARg transcriptional program and promotes the nonphosphorylated PPARg serine 273 state in these cells. This leads to increased adipogenesis, reduced adipose tissue ATM content and inflammation, improved cell autonomous adipocyte insulin sensitivity, changes in adipokine secretion, and increased systemic insulin sensitivity, all of which phenocopy the TZD treated in vivo state. Thus, while NCoR can corepress multiple nuclear receptors, these data demonstrate selective cell type effects of this corepressor, indicating that it's dominant action in adipocytes is to corepress PPARg. These results raise the possibility that NCoR may prove to be a useful target for future therapeutics in the treatment of Type 2 diabetes and other insulin resistant diseases.
EXPERIMENTAL PROCEDURES
Creation of Control and Adipocyte-Specific NCoR Knockout Mice Mice carrying floxed alleles of NCoR were provided by Dr. Johan Auwerx. These mice were backcrossed to the C57BL/6J strain for nine generations. Mice were bred with transgenic mice harboring Cre recombinase driven by aP2 promoter (He et al., 2003) to create the following genotypes: NCoRfl/fl (control), NCoRfl/fl-ap2Cre (AKO).
ITTs, GTTs, and Hyperinsulinemic Euglycemic Clamp Study
Glucose and insulin tolerance tests were performed on 6 hr fasted mice. For GTTs, animals were IP injected with dextrose (1 g/kg, Hospira, Inc), whereas for ITTs 0.5 units/kg of insulin (Novolin R, Novo-Nordisk) was IP injected. Blood was drawn at 0, 15, 30, 60, and 120 min after dextrose or 0, 15, 30, 60, and 90 min after insulin injection. Mouse clamps were performed as previously described (He et al., 2003; Li et al., 2010; Lu et al., 2010) . Briefly, dual catheters (MRE-025, Braintree Scientific) were implanted in the right jugular vein and tunneled subcutaneously and exteriorized at the back of the neck. The mice were allowed to recover for 3 to 4 days before the clamp procedure. After 6 hr fasting, the clamp experiments began with a constant infusion (5 mCi/hr) of D-[3-3H] glucose (Du Pont-NEN, Boston, MA). After 90 min of tracer equilibration and basal sampling at t = -10 and 0 min, glucose (50% dextrose, variable infusion; Abbott) and tracer (5 mCi/hr) plus insulin (6 mU/kg/min) were infused into the jugular vein. Blood from the tail vein was drawn at 10 min intervals and analyzed for glucose to maintain the integrity of the glucose clamp. Blood was taken at t = -10, 0 (basal), 110, and 120 (end of experiment) min to determine glucose-specific activity, insulin, and free fatty acids (FFA). Steady-state conditions (120 mg/dl ± 5 mg/dl) were confirmed at the end of the clamp by ensuring that glucose infusion and plasma glucose levels were maintained constant for a minimum of 30 min. HGP and GDR were calculated in the basal state and during the steady-state portion of the clamp. Tracerdetermined rates were quantified by using the Steele equation (Steele, 1959) . At steady state, the rate of glucose disappearance, or total GDR, is equal to the sum of the rate of endogenous glucose productions (HGP) plus the exogenous (cold) GIR. The IS-GDR is equal to the total GDR minus the basal glucose turnover rate.
Adipocyte Isolation, SVCs Isolation, and FACS Analysis Adipocyte, SVCs isolation, and FACS analysis were performed as previously described . Briefly, epididymal fat pads were weighed, rinsed three times in PBS, and then minced in FACS buffer (PBS + 1% low endotoxin BSA). Tissue suspensions were treated with collagenase (1 mg/ml, Sigma-Aldrich) for 30 min, and then were filtered through a 100 mm filter (BD Biosciences). After centrifugation at 500 g for 5 min, the supernatant containing adipocytes was removed and the pallet containing SVCs fraction was incubated with RBC lysis buffer (eBioscience) for 5 min followed by another centrifugation (300 g, 5 min) and resuspension in FACS buffer. SVCs were incubated with Fc Block (BD Biosciences) for 20 min at 4 C before staining with fluorescently labeled primary antibodies or control IgGs for 30 min at 4 C. F4/80-APC FACS antibody was purchased from AbD Serotec (Raleigh, NC); FITC-CD11b and PE-CD11c FACS antibodies were from BD Biosciences. Cells were gently washed twice and resuspended in FACS buffer with propidium iodide (Sigma). SVCs were analyzed using a FACSAria flow cytometer (BD Biosciences). Unstained, single stains and Fluorescence Minus One controls were used for setting compensation and gates. The events were first gated based on forward-area versus side scatter-area as well as side scatter-height versus side scatter-width and forward scatter-height versus forward scatter-width for a total of three dual parameter plots to gate out aggregates and debris. Single color controls were used to calculate compensation using the FACSDiva software. A plot of forward scatter versus propidium iodide was used as the fourth gate to identify individual, live cells. To measure markers with the maximum sensitivity, each fluorochrome was plotted versus propidium iodide, and polygons were drawn, angled with the aid of the Fluorescence Minus One controls.
Confocal Microscopy of Mouse Adipose Tissue
The method for immunofluorescene study of mouse adipose tissue was carried out as previously described (Lumeng et al., 2008) . Briefly, mice were euthanized and slowly perfused with 10 ml of 1% paraformaldehyde in PBS via intracardiac injection. 1 cm 3 fat-pad samples were excised and blocked for 1 hr in 5% BSA in PBS with gentle rocking at RT. For detection of intracellular antigens, samples were blocked in 5% BSA in PBS and subsequently permeabilized in 0.3% Triton X-100. Fat samples were incubated with primary antibodies in blocking buffer (0.5-1 mg/ml) for overnight at 4 C. After three washes, samples were incubated with fluorochrome-conjugated secondary antibodies for 1 hr at RT. Fat pads were imaged on an inverted confocal microscope (Olympus Fluoview 1000). Anti-F4/80 and caveolin1 were purchased from Abcam and BD Biosciences, respectively.
In Vivo Tracking Assay Monocyte Preparation
Leukocyte pools from C57BL/6 male mice 12 weeks of age, bled from the retro orbital sinus, were subjected to red blood cell lysis and monocyte subsets were enriched with EasySep mouse monocyte enrichment kit (STEMCELL tech, Vancouver, BC) followed the manufacturer's instructions. In Vitro Labeling Isolated monocytes (5 3 10 6 to 10 3 10 6 ) were washed once in serum-free medium (RPMI-1640) and suspended in 2 ml of Diluent solution C (included in the PKH26 labeling kit). Two ml of PKH26 (Sigma Chemical Co. St Louis, MO) at 2 3 10 À3 M in Diluent C was added and mixed, and the cells were incubated for 10 min at room temperature in the dark. The staining reaction was halted by addition of an equal volume (2 ml) of medium supplemented with 10% FBS. The mixture was centrifuged and the cells were washed once and resuspended in serum-containing medium.
In Vivo Migration Subsequent to labeling with PKH26 monocytes were counted and $1 3 10 6 viable cells were suspended in 0.2 ml PBS and injected into the femoral vein of the recipient mice. Two days after injection, the ATMs were immediately isolated from visceral fat tissue and analyzed by FACS.
Other Methods See Supplemental Information.
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